Ellison, Stephen
Abdulrahim, Jawan W.
Kwee, Lydia Coulter
Bihlmeyer, Nathan A.
Pagidipati, Neha
McGarrah, Robert
Bain, James R.
Kraus, William E.
Shah, Svati H.
Funding for this research was provided by:
National Institutes of Health (R01-HL127009, R01-HL127009)
American Heart Association (17SFRN33670990)
National Heart, Lung, and Blood Institute (5P01-HL036587)
Article History
Received: 15 April 2020
Accepted: 18 November 2020
First Online: 7 December 2020
Competing interests
: Dr. Pagidipati’s work has been funded by: Amarin Pharmaceutical Company; Amgen, Inc.; AstraZeneca; Baseline Study LLC; Boehringer Ingleheim; Duke Clinical Research Institute; Eli Lilly & Company; Novo Nordisk Pharmaceutical Company; Regeneron Pharmaceuticals, Inc.; Sanofi-S.A.; Verily Sciences Research Company. She reports consulting fees from AstraZeneca; Boehringer Ingleheim; Esperion Therapeutics. Dr. Ellison, Dr. Kwee, Dr. Bihlmeyer, Dr. Abdulrahim, Dr. McGarrah, and Dr. Bain declare no potential competing interests. Dr. Shah and Dr. Kraus have an unlicensed patent on a related research finding and Dr. Shah receives sponsored research funding from Baseline Study LLC.